期刊
JOURNAL OF NUCLEAR MEDICINE
卷 50, 期 -, 页码 97S-105S出版社
SOC NUCLEAR MEDICINE INC
DOI: 10.2967/jnumed.108.057273
关键词
F-18-FDG PET; cytostatic treatment; cytoreductive therapy; response monitoring; imatinib mesylate
资金
- Cancer Research U.K. [C2536/A5708, C37/A5610]
- U.K. Medical Research Council [U1200.02.005.00001.01]
- MRC [MC_U120081322] Funding Source: UKRI
- Cancer Research UK [10337] Funding Source: researchfish
- Medical Research Council [MC_U120081322] Funding Source: researchfish
F-18-FDG PET and, more recently, PET/CT have been established as response biomarkers for monitoring cytotoxic or cytoreductive cancer therapies. With the advent of targeted cancer therapies, which are predominantly cytostatic, F-18-FDG PET is increasingly being used to monitor the therapeutic response to these agents as well. The impressive outcome of F-18-FDG PET studies in patients with gastrointestinal stromal tumors treated with imatinib mesylate brought to the forefront the use of this biomarker for assessing the response to targeted therapies. The use of F-18-FDG PET for this purpose has practical challenges, including quantitative analysis and timing of scans. This review provides a summary of clinical studies of targeted therapies done to date with F-18-FDG PET and provides guidance on practical issues to ensure the optimal interpretation of imaging data in drug development and for patient care.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据